TransMedics Group, Inc. director James R. Tobin filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 4,059 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Seller: James R. Tobin, identified in the filing as a Director of TransMedics Group, Inc.
  • Shares proposed for sale: 4,059 shares of common stock, with an aggregate market value of $385,467.75 according to the filing.
  • Approximate sale date: November 9, 2026, through NASDAQ.
  • Shares outstanding: The filing reports 34,733,883 shares of common stock outstanding.
  • Source of shares: The shares were acquired as restricted stock from the issuer across three separate grants: 1,193 shares on May 23, 2024; 732 shares on May 22, 2025; and 2,134 shares on May 20, 2026.
  • Prior sales: The filing indicates nothing to report for securities sold in the past three months.

TransMedics Director Tobin Files Rule 144 Notice for Restricted Stock Sale

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, James R. Tobin, a director of TransMedics Group, Inc. (NASDAQ:TMDX), proposed to sell 4,059 shares of the company's common stock. The filing lists an aggregate market value of $385,467.75 for the proposed sale, with Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza, 8th Floor, New York, NY 10004 named as the broker.

The shares subject to this notice were acquired entirely through restricted stock grants from the issuer. The filing identifies three separate acquisition dates and amounts: 1,193 shares acquired on May 23, 2024; 732 shares acquired on May 22, 2025; and 2,134 shares acquired on May 20, 2026. The filing records no payment consideration beyond the restricted stock arrangements and notes no securities sold in the prior three months by the reporting person.

By signing the notice, Tobin represented, as stated in the form, that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." The filing does not indicate whether a Rule 10b5-1 trading plan is in place. TransMedics Group, Inc. is headquartered at 200 Minuteman Road, Andover, Massachusetts 01810, and its SEC file number is listed as 001-38891.

What Was Disclosed

A Form 144 notice filed November 9, 2026 discloses TransMedics director James R. Tobin's proposed sale of 4,059 restricted stock shares with an aggregate market value of $385,467.75, acquired in three grants between May 2024 and May 2026.